Thursday 22 October 2026
Export XNCR’s income statement to Excel — free account
Xencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024. In the quarter to June 2026, revenue grew 17.5%, EPS grew 29.3% and free cash flow fell 52.9%, each against the same quarter a year earlier.
25.90
0.74
+2.94%
Follow XNCR
Xencor, Inc. (XNCR) P/E ratio
Xencor, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 89.2× (July 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 28.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 70.2× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 23.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 39 more quarters | Free account |
Against its own ten years
Low 0.0×
High 89.2×
Ten-year median
0.0×
Current reading's percentile
72
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NVAX Novavax, Inc. compare | n/m |
| ZBIO Zenas BioPharma, Inc. compare | n/m |
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| XNCR Xencor, Inc. | n/m |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| BRVE Braveheart Bio, Inc. compare | — |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 23.6× |
| Market median | 18.4× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)